1704. Zika: Evolution of Diagnostics and Neurodevelopmental Outcome in Congenital Zika Infection
Session: Symposium: Neonatal Infectious Disease: Chagas, Zika, and LCMV
Saturday, October 6, 2018: 8:45 AM
Room: W 2014-2016
Margaret (Peggy) Honein, PhD, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA

Margaret (Peggy) Honein, PhD, MPH is an epidemiologist and Director of CDC’s Division of Congenital and Developmental Disorders. Dr. Honein received her BS degree in Biology from the University of California, Riverside in 1986, her MPH from the University of California, Los Angeles (UCLA) in 1992, and her PhD in Epidemiology from UCLA in 1995, and joined CDC as an EIS officer in 1997. She completed her doctoral dissertation research on HIV among tuberculosis patients in the East African country Djibouti. Most recently, Dr. Honein served as the co-lead for the Pregnancy and Birth Defects Task Force throughout over 20 months of CDC’s Emergency Zika Response; in this capacity, she developed and directed work to advance understanding of and mitigate the impact of Zika virus infection during pregnancy. Dr. Honein also served as the Epidemiology Lead for the Maternal Health team during the 2009/10 Influenza Pandemic Response, a critical component of CDC’s efforts to protect the health of pregnant women and infants. Dr. Honein has published over 150 scientific papers in the field of birth defects, and her research interests include understanding the role of smoking in birth defects, assessing the safety or risk of medication use and vaccine use during pregnancy, identifying congenital infections with adverse neonatal and infant outcomes, and understanding longer term outcomes and costs associated with congenital heart defects and other birth defects. She has extensively mentored junior scientists at CDC over the past 21 years.


M. Honein, None

Previous Presentation | Next Presentation >>

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.